EE200100520A - N-(2-fenüül-4-aminobutüül)-1-naftamiidid neurokiniin-1-retseptori antagonistidena - Google Patents

N-(2-fenüül-4-aminobutüül)-1-naftamiidid neurokiniin-1-retseptori antagonistidena

Info

Publication number
EE200100520A
EE200100520A EEP200100520A EEP200100520A EE200100520A EE 200100520 A EE200100520 A EE 200100520A EE P200100520 A EEP200100520 A EE P200100520A EE P200100520 A EEP200100520 A EE P200100520A EE 200100520 A EE200100520 A EE 200100520A
Authority
EE
Estonia
Prior art keywords
naphthamides
neurokinin
aminobutyl
phenyl
receptor antagonists
Prior art date
Application number
EEP200100520A
Other languages
English (en)
Estonian (et)
Inventor
Robert Bernstein Peter
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of EE200100520A publication Critical patent/EE200100520A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/57—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EEP200100520A 1999-04-06 2000-04-03 N-(2-fenüül-4-aminobutüül)-1-naftamiidid neurokiniin-1-retseptori antagonistidena EE200100520A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9907571.5A GB9907571D0 (en) 1999-04-06 1999-04-06 Compounds
PCT/GB2000/001252 WO2000059873A1 (en) 1999-04-06 2000-04-03 N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists

Publications (1)

Publication Number Publication Date
EE200100520A true EE200100520A (et) 2002-12-16

Family

ID=10850835

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100520A EE200100520A (et) 1999-04-06 2000-04-03 N-(2-fenüül-4-aminobutüül)-1-naftamiidid neurokiniin-1-retseptori antagonistidena

Country Status (25)

Country Link
US (3) US6476077B1 (de)
EP (1) EP1169302B1 (de)
JP (1) JP2002541137A (de)
KR (1) KR20010102580A (de)
CN (2) CN1345307A (de)
AT (1) ATE277893T1 (de)
AU (1) AU3569200A (de)
BG (1) BG106074A (de)
BR (1) BR0009582A (de)
CA (1) CA2368240A1 (de)
CZ (1) CZ20013574A3 (de)
DE (1) DE60014343T2 (de)
EE (1) EE200100520A (de)
GB (1) GB9907571D0 (de)
HK (1) HK1044145A1 (de)
HU (1) HUP0200707A3 (de)
IL (1) IL145645A0 (de)
IS (1) IS6087A (de)
NO (1) NO20014855L (de)
PL (1) PL350568A1 (de)
SK (1) SK13012001A3 (de)
TR (1) TR200102875T2 (de)
UA (1) UA67839C2 (de)
WO (1) WO2000059873A1 (de)
ZA (1) ZA200108176B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9907571D0 (en) 1999-04-06 1999-05-26 Zeneca Ltd Compounds
GB0019008D0 (en) * 2000-08-04 2000-09-27 Astrazeneca Ab Therapeutic compounds
SE0201938D0 (sv) * 2002-06-20 2002-06-20 Astrazeneca Ab New process
JP2006505461A (ja) * 2002-11-05 2006-02-16 アストラゼネカ・アクチエボラーグ 錠止蓋を有する安全容器および蓋を錠止する方法
EP1581495B1 (de) * 2002-12-20 2007-04-18 AstraZeneca AB 4-Aryl-4-(Naphth-1-ylmethylamino)methyl-Piperidin-Verbindungen und deren Verwendung
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
US20060069086A1 (en) * 2004-09-23 2006-03-30 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
WO2013004766A1 (en) 2011-07-04 2013-01-10 Ferrari Giulio Nk-1 receptor antagonists for treating corneal neovascularisation
AU2016264034B2 (en) 2015-05-18 2020-03-05 KaNDy Therapeutics Limited Dual NK-1/NK-3 receptor antagonists for the treatment of sex-hormone-dependent diseases
RU2020131446A (ru) 2018-02-26 2022-03-28 Оспедале Сан Раффаэле С.Р.Л. Антагонисты nk-1 для применения в лечении глазной боли
EA202092131A1 (ru) 2018-03-14 2020-11-27 Кэнди Терапьютикс Лимитед Новый фармацевтический препарат, содержащий двойные антагонисты рецептора nk-1/nk-3
RU2697414C1 (ru) 2018-05-11 2019-08-14 Общество с ограниченной ответственностью "АЙ БИ ДИ Терапевтикс" Новый антагонист тахикининовых рецепторов и его применение
EP4117673A1 (de) 2020-03-11 2023-01-18 Ospedale San Raffaele S.r.l. Behandlung von stammzellenmangel
US12533358B1 (en) 2025-05-14 2026-01-27 Bayer Consumer Care Ag Methods of treatment with elinzanetant

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI97540C (fi) 1989-11-06 1997-01-10 Sanofi Sa Menetelmä terapeuttisesti käyttökelpoisten, aromaattisesti substituoitujen piperidiini- ja piperatsiinijohdannaisten valmistamiseksi
EP0702681A1 (de) 1993-06-07 1996-03-27 Merck & Co. Inc. Spiro-substituierte azaringe als neurokinin antagonisten
ES2157337T3 (es) * 1994-08-15 2001-08-16 Merck Sharp & Dohme Derivados de morfolina y su uso como agentes terapeuticos.
AU5522498A (en) 1996-12-13 1998-07-03 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
GB9907571D0 (en) * 1999-04-06 1999-05-26 Zeneca Ltd Compounds
AU2002247367B2 (en) * 2001-03-21 2005-10-27 Pharmacopeia Drug Discovery, Inc. Aryl and biaryl compounds having MCH modulatory activity

Also Published As

Publication number Publication date
TR200102875T2 (tr) 2002-01-21
HUP0200707A3 (en) 2002-11-28
CN1345307A (zh) 2002-04-17
HK1044145A1 (zh) 2002-10-11
ATE277893T1 (de) 2004-10-15
US6476077B1 (en) 2002-11-05
CN1534017A (zh) 2004-10-06
KR20010102580A (ko) 2001-11-15
HUP0200707A2 (en) 2002-06-29
DE60014343D1 (de) 2004-11-04
EP1169302B1 (de) 2004-09-29
JP2002541137A (ja) 2002-12-03
IL145645A0 (en) 2002-06-30
ZA200108176B (en) 2003-01-06
EP1169302A1 (de) 2002-01-09
PL350568A1 (en) 2002-12-16
UA67839C2 (uk) 2004-07-15
IS6087A (is) 2001-09-26
NO20014855D0 (no) 2001-10-05
BR0009582A (pt) 2001-12-26
BG106074A (en) 2002-05-31
GB9907571D0 (en) 1999-05-26
US6821973B2 (en) 2004-11-23
WO2000059873A1 (en) 2000-10-12
US20030092713A1 (en) 2003-05-15
SK13012001A3 (sk) 2002-04-04
AU3569200A (en) 2000-10-23
NO20014855L (no) 2001-12-06
US6586432B2 (en) 2003-07-01
CZ20013574A3 (cs) 2002-05-15
CA2368240A1 (en) 2000-10-12
DE60014343T2 (de) 2006-03-02
US20040106610A1 (en) 2004-06-03

Similar Documents

Publication Publication Date Title
DE60030741D1 (de) Chinazoline verbindungen als heilmittel
EE200300403A (et) N-asendatud mittearomaatne heterotsükliline ühend, seda sisaldav ravimkompositsioon ning ühendi kasutamine ravimina
BRPI0417717A (pt) composto, composição farmacêutica, e, uso de um composto
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
EA200200571A1 (ru) Новая композиция и ее применение
MXPA05007609A (es) Antagonista de un receptor sensible al calcio.
NO20020282D0 (no) Nytt difenylpiperidinderivat
MXPA04003730A (es) Derivados del 3-azabiciclo[3.1.0]hexano.
NO20014855D0 (no) N-(2-fenyl-4-aminobutyl)-1-naftamider som neurokinin-1- reseptorantagonister
ATE308522T1 (de) Opioidrezeptorantagonisten
ATE369348T1 (de) Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie
DE60134735D1 (de) Neue neurokinin-antagonisten zum gebrauch als arzneimittel
DE69917005D1 (de) Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung
DK0758312T3 (da) Substituerede fusionerede og broforbundne bicykliske forbindelser som terapeutiske midler
ATE384066T1 (de) Thieno-pyrrole verbindungen als antagonisten der gonadotropin-freisetzenden hormonrezeptoren
ATE420860T1 (de) N-substituierte amide als nk1 rezeptor antagonisten
DE60110233D1 (de) Neue n-(2-phenyl-3-aminopropyl)naphtamide
DE60114597D1 (de) Naphthamid-neurokinin antagonisten zur verwendung als medikamente
EA200401617A1 (ru) Комбинация nmda-антагониста и ингибиторов ацетилхолинэстеразы для лечения болезни альцгеймера
NO20014889L (no) Fremgangsmåte for fremstilling av medisinske midler